Open Access

Stelara (ustekinumab) is a medicine that is used to treat severe or moderate plaque psoriasis or psoriatic arthritis in adults.it is available in 2 forms- solutions and injections. It interfere with inflammatory response of body by blocking interleukin 12 and interleukin 23 that are naturally occuring proteins which regulate immune system and immune mediated inflammatory disorders. It is not administered to patients who have tuberculosis (active), cancer, pregnancy and those who received a BCG vaccine in past 12 months. The product has 27 major, 290 moderate, and 15 minor drug interactions. STELARA is created in an all around described recombinant cell line and is cleansed utilizing standard bio-preparing innovation. The assembling procedure contains ventures for the freedom of infections. STELARA is involved 1326 amino acids and has an expected sub-atomic mass that ranges from 148,079 to 149,690 Daltons. 
STELARA, for subcutaneous utilization, is accessible as: 45 mg of ustekinumab in 0.5 mL and 90 mg of ustekinumab in 1 mL. STELARA is supplied as a sterile arrangement in a solitary utilization prefilled syringe with a 27 gage altered ½ inch needle, or a solitary utilize 2 mL Type I glass vial with a covered plug. The syringe is fitted with a detached needle watchman and a needle cover that is made utilizing a dry regular elastic (a subordinate of late

Related Journals of Stelara 
Psoriasis & Rosacea Open Access, Clinical Pediatrics & Dermatology, Journal of Clinical & Experimental Dermatology Research, Dermatology Case Reports, Journal of Dermatitis, Cosmetic Dermatology, Current problems in dermatology, Dermatology, Dermatology and Therapy, Dermatology Online Journal, Dermatology Reports, Dermatology Research and Practice

Stelara

Conference Proceedings